Search - tctmd.com

Displaying 81 - 94 of 94

Sort: Relevancy | Date

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

Advertisement

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 2021 News Roundup

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content